The concept of value-based healthcare: opportunities for drug pricing
DOI: https://doi.org/10.29296/25419218-2020-05-06
Issue:
5
Year:
2020
The paper reviews methodological approaches to value-based pricing (VBP), within which the principles of determining the values of drugs and converting the resulting value into a price. At the value determination stage, the investigators identify two main approaches: 1) to use the indicator the number of years of life in terms of its quality (quality-adjusted life-year (QALY)) as a value criterion and 2) to determine multicriteria values. On this evidence, an approach to calculating the drug price is subsequently determined. The classic approach is to use the cost-effectiveness analysis and the established willingness-to-pay threshold for an additional QALY; however, it does not make it possible to take into account all aspects of value and requires that cost-effectiveness should be used as the main driver in making a reimbursement decision. The alternative approaches are to determine the willingness to pay per unit of aggregate value (taking into account multiple criteria) using the net monetary benefit method or establishing a premium system in terms of a drug’s value level. Currently, only the United Kingdom fully uses cost-effective VBP, while other countries employ its elements.
Keywords:
value-based pricing
pharmaceuticals
quality-adjusted life years
multicriteria decision making analysis
QALY
MCDA
References:
- Porter M.E., Lee T.H. From Volume to Value in Health Care: The Work Begins. JAMA. 2016; 316 (10): 1047–8. DOI: 10.1001/jama.2016.11698
- Garrison L.P., Towse A. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. J. Pers. Med., 2017; 7 (3): 10. DOI: 10.3390/jpm7030010
- Garner S., Rintoul A., Hill S.R. Value-Based Pricing: L’Enfant Terrible?. Pharmacoeconomics, 2018; 36 (1): 5–6. DOI: 10.1007/s40273-017-0567-4
- Moreno S.G., Ray J.A. The value of innovation under value-based pricing. J. Mark. Access. Health Policy. 2016; 4. DOI: 10.3402/jmahp.v4.30754.
- Jommi C., Armeni P., Costa F. et al. Implementation of value-based pricing for medicines. Clinical therapeutics, 2019; 42 (1): 15–24. DOI: 10.1016/j.clinthera.2019.11.006
- Kanavos P., Manning J., Taylor D. et al. Implementing value-based pricing for pharmaceuticals in the UK. London: 2020 health. 2010.
- Keckley P.H., Snyder G. Value Based Pricing for Pharmaceuticals, Implications of the Shift from Volume to Value. Deloitte Center for Health Solutions, 2012.
- Sussex J., Towse A., Devlin N. Operationalizing value-based pricing of medicines: a taxonomy of approaches. Pharmacoeconomics. 2013; 31: 1–10. DOI: 10.1007/s40273-012-0001-x
- Net Monetary Benefit [online]. York; York Health Economics Consortium; 2016. [Electronic resource]. Access mode: https://yhec.co.uk/glossary/net-monetary-benefit (circulation date: 15.06.2020).
- Paulden M. Recent amendments to NICE’s value-based assessment of health technologies: implicitly inequitable? Expert .Rev. Pharmacoecon. Outcomes. Res., 2017; 17 (3): 239–42. DOI: 10.1080/14737167.2017.1330152
- National Institute of Health and Clinical Excellence. Changes to NICE drug appraisals: what you need to know. [Electronic resource]. Access mode: https://www.nice.org.uk/news/feature/changes-to-nice-drug-appraisals-what-you-need-to-know
- National Institute of Health and Clinical Excellence. Centre for health technology evaluation. Consultation Paper Value Based Assessment of Health Technologies. [Electronic resource]. Access mode: https://www.nice.org.uk/Media/Default/About/what-we-do/NIC
- Omel'janovskij V.V., Nikitina A.V., Lemeshko V.A., Hachatrjan G.R. Lekarstvennoe obespechenie i otsenka tehnologij zdravoohranenija vo Frantsii. FARMAKOEKONOMIKA. Sovremennaja farmakoekonomika i farmakoepidemiologija. 2020; 13 (1): 71–83. DOI: 10.17749/2070 [Omelyanovskiy V.V., Nikitina A.V., Lemeshko V.A., Khachatryan G.R. Drug provision and health technology assessment in France. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya, 2020; 13 (1): 71–83. DOI: 10.17749/2070-4909.2020.13.1.71-83 (in Russian)]
- Wenzl M., Paris V. Pharmaceutical reimbursement and pricing in Germany. 2018.
- Rahmenvereinbarungnach § 130b Abs. 9 SGB V. [Electronic resource]. Access mode: https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/rahmenvertraege/pharmazeutische_unternehmer/Rahmenvereinbarung_130b_Abs9__SGB_V_2016.pdf
- Gorkavenko F.V., Omel'janovskij V.V., Bezdenezhnyh T.P., Hachatrjan G.R. Otsenka tehnologij zdravoohranenija i sistema lekarstvennogo vozmeschenija v Italii. FARMAKOEKONOMIKA. Sovremennaja farmakoekonomika i farmakoepidemiologija. 2019; 12 (2): 156–64. DOI: 10.17749/2070-4909.2019.12.2.156-164 [Gorkavenko F.V., Omelyanovskiy V.V., Bezdenezhnykh T.P., Khachatryan G.R. Health technology assessment and reimbursement of pharmaceuticals in Italy. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2019; 12 (2): 156–64. DOI: 10.17749/2070-4909.2019.12.2.156-164 (in Russian)